Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
akkermansia muciniphila-derived extracellular vesicles
- Development stage
- Preclinical
- Lead developer
- Korea Food Research Institute
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
Akkermansia muciniphila-derived extracellular vesicles (AmEVs) are nano-sized vesicles (approximately 90-95 nm) secreted by the beneficial gut bacterium *Akkermansia muciniphila*. These vesicles contain bioactive macromolecules, including proteins and lipids, that mediate the bacterium's therapeutic effects without the need for live bacterial colonization. AmEVs function by enhancing intestinal barrier integrity through the regulation of tight junction proteins, modulating inflammatory responses via Toll-like receptor (TLR2/4) signaling pathways, and influencing the gut-brain axis. Preclinical studies have demonstrated their potential in treating metabolic disorders (obesity, type 2 diabetes), inflammatory bowel disease, and neurological conditions such as ischemic stroke and cognitive dysfunction. In stroke models, intravenous administration has been shown to cross the blood-brain barrier, reduce neuroinflammation, and promote myelin repair by activating astrocyte-derived pleiotrophin (PTN)–PTPRZ1 signaling.
- Other names
- Akkermansia muciniphila extracellular vesiclesAkkermansia muciniphila outer membrane vesicles
02
Targets
OCLN (Occludin)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)PTPRZ1 (Protein tyrosine phosphatase receptor type Z1)
Beyond the preview
Go deeper on akkermansia muciniphila-derived extracellular vesicles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on akkermansia muciniphila-derived extracellular vesicles.